Hot Features
Registrieren Sie sich für Echtzeit-Benachrichtigungen, benutzerdefinierte Portfolios und Marktbewegungen.
Roche enters into a definitive agreement to acquire Poseida Therapeutics, including cell therapy candidates and related platform technologies Acquisition supports Roche’s Pharma Strategy and...
Roche reports update on Phase III SKYSCRAPER-01 study results Basel, 26 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) reports an update on the phase III SKYSCRAPER-01 study, evaluating...
Roche to present new and encouraging long-term follow-up data across broad haematology portfolio at ASH 2024 Basel, 05 November 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it...
Roche presents new data at CTAD, demonstrating its growing momentum in diagnostics for Alzheimer’s disease New data highlight the potential of the Roche Elecsys® Amyloid Plasma Panel and Elecsys...
New England Journal of Medicine publishes landmark phase III results for Roche’s Itovebi, showing more than doubling of progression-free survival in certain type of HR-positive advanced breast...
[Ad hoc-Mitteilung gemäss Art. 53 KR] Starkes Verkaufswachstum der Roche-Gruppe von 9% (CER) auch im dritten Quartal 2024; Konzernverkäufe steigen in den ersten neun Monaten um 6% Konzernverkäufe...
[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong sales growth of 9% (CER) continues in the third quarter of 2024; Group sales increase 6% in the first nine months Group sales grew by...
Roche’s Vabysmo improved vision in underrepresented populations with diabetic macular edema (DME) in a first-of-its-kind study The ELEVATUM study showed clinically meaningful improvement in vision...
Majority of children with spinal muscular atrophy (SMA) treated with Roche’s Evrysdi are able to sit, stand and walk independently, two-year data demonstrate Positive data confirm Evrysdi efficacy...
FDA approves Roche’s Itovebi, a targeted treatment for advanced hormone receptor-positive, HER2-negative breast cancer with a PIK3CA mutation Approval is based on Phase III INAVO120 results...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0 | 0 | 229.2 | 229.2 | 229.2 | 7689 | 229.2 | DE |
| 4 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4568 | 229.2 | DE |
| 12 | 0 | 0 | 229.2 | 229.2 | 229.2 | 5382 | 229.2 | DE |
| 26 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4331 | 229.2 | DE |
| 52 | 0 | 0 | 229.2 | 229.2 | 229.2 | 5079 | 229.2 | DE |
| 156 | 0 | 0 | 229.2 | 229.2 | 229.2 | 6036 | 229.2 | DE |
| 260 | 0 | 0 | 229.2 | 229.2 | 229.2 | 4866 | 229.2 | DE |
Die zuletzt besuchten Aktien werden in diesem Feld angezeigt, so dass Sie leicht zu den Aktien zurückkehren können, die Sie zuvor angesehen haben.
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
